Protagonist Therapeutics Stock Alpha and Beta Analysis
| PTGX Stock | USD 45.53 0.93 2.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Protagonist Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Protagonist Therapeutics over a specified time horizon. Remember, high Protagonist Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Protagonist Therapeutics' market risk premium analysis include:
Beta 1.64 | Alpha (0.03) | Risk 2.8 | Sharpe Ratio 0.0493 | Expected Return 0.14 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Protagonist |
Protagonist Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Protagonist Therapeutics market risk premium is the additional return an investor will receive from holding Protagonist Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Protagonist Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Protagonist Therapeutics' performance over market.| α | -0.03 | β | 1.64 |
Protagonist Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Protagonist Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Protagonist Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Protagonist Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Protagonist Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Protagonist Therapeutics shares will generate the highest return on investment. By understating and applying Protagonist Therapeutics stock market price indicators, traders can identify Protagonist Therapeutics position entry and exit signals to maximize returns.
Protagonist Therapeutics Return and Market Media
The median price of Protagonist Therapeutics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 45.0 with a coefficient of variation of 5.07. The daily time series for the period is distributed with a sample standard deviation of 2.27, arithmetic mean of 44.78, and mean deviation of 1.87. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Protagonist Therapeutics, Inc. Receives 49.86 Consensus PT from Analysts | 10/14/2024 |
2 | Protagonist Therapeutics is on the Move, Heres Why the Trend Could be Sustainable | 10/15/2024 |
3 | Protagonist Therapeutics Inc. Advancing Treatments for Autoimmune Diseases | 10/18/2024 |
4 | Vanguard Group Incs Strategic Acquisition in Protagonist Therapeutics Inc | 11/05/2024 |
5 | Protagonist Therapeutics Inc Q3 2024 Earnings EPS Loss of 0. ... | 11/07/2024 |
6 | Disposition of 1906 shares by Molina Arturo Md of Protagonist Therapeutics at 40.98 subject to Rule 16b-3 | 11/15/2024 |
7 | Protagonist Therapeutics chief medical officer sells 78,107 in stock | 11/19/2024 |
8 | Truist maintains Buy on PTGX with 60 target | 11/22/2024 |
About Protagonist Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Protagonist or other stocks. Alpha measures the amount that position in Protagonist Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 (projected) | Current Ratio | 7.74 | 7.61 | 16.71 | Net Debt To EBITDA | 0.96 | 0.93 | 2.05 |
Protagonist Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Protagonist Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Protagonist Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Protagonist Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Protagonist Therapeutics. Please utilize our Beneish M Score to check the likelihood of Protagonist Therapeutics' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Protagonist Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.